Skip to content

Feedback on 85% Rebate for MBS Item 18379

In 2025, the Department of Health and Aged Care removed the 85% rebate level for several procedural items. This followed a review which deemed certain procedures should be performed only in hospital or a hospital equivalent setting.

USANZ and ANZAUS advocated that the 85% rebate for certain items be reinstated. As part of this process, ANZAUS is seeking Member feedback on Item 18379, as performed outside of a hospital or hospital-equivalent setting. Item 18379 refers to Botulinum Toxin Type A Purified Neurotoxin Complex (Botox), intravesical injection of, with cystoscopy, for the treatment of urinary incontinence.

For additional information on the 85% rebate, access the Department's Guidance on Claiming 75 / 85 / 100% Benefits Under Medicare.

Please complete the brief survey below to help inform ANZAUS's response to the Department.
1.Do you perform item 18379 outside of a hospital or hospital-equivalent (e.g. Day Surgery) setting (e.g. in rooms)?
2.If so, how many times per year would you perform the procedure?
3.If not, do you envisage ever performing this procedure out of a hospital or a hospital-equivalent setting?